SEC Form 10-Q filed by Sana Biotechnology Inc.
$SANA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/26/2024 | $16.00 | Buy | Rodman & Renshaw |
| 1/16/2024 | $12.00 | Neutral → Buy | H.C. Wainwright |
| 9/25/2023 | $9.00 | Mkt Outperform | JMP Securities |
| 9/5/2023 | $8.00 | Buy | Citigroup |
| 8/14/2023 | Market Perform | TD Cowen | |
| 5/2/2023 | Neutral | H.C. Wainwright | |
| 8/6/2021 | $39.00 → $34.00 | Neutral | Goldman Sachs |
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
3/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
3 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
JMP Securities downgraded Sana Biotechnology from Mkt Outperform to Mkt Perform
Rodman & Renshaw initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $16.00
H.C. Wainwright upgraded Sana Biotechnology from Neutral to Buy and set a new price target of $12.00
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin miceAdditional proof-of-concept for the advancement of SC379, Sana's pluripotent stem cell-derived glial progenitor cell product candidate
HC Wainwright & Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:SANA) with a Buy and maintains $12 price target.
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)